Table 3 |
||||
|
Stock of sulphadoxine pyrimethamine on the day of survey, TNVS RCH Facility Survey 2005–07 |
||||
|
2005 |
2006 |
2007 |
χ2 (p-value)1 |
|
|
|
||||
|
All |
84.7 (78.8–89.2) [N = 190] |
74.5 (67.7–80.2) [N = 188] |
59.5 (52.2–66.1) [N = 192] |
20.6 (< 0.001) |
|
By level of facility |
||||
|
Dispensary |
84.7 (77.9–89.6) [N = 150] |
71.3 (63.1–78.3) [N = 136] |
55.6 (47.3–63.5) [N = 144] |
19.3 (< 0.001) |
|
Health Centre |
95.2 (72.5–99.3) [N = 21] |
80.6 (62.9–91.1) [N = 31] |
72.4 (53.6–85.6) [N = 29] |
3.2 (0.04) |
|
Hospital |
73.7 (50.0–88.7) [N = 19] |
85.7 (63.6–95.3) [N = 21] |
68.4 (44.9–85.2) [N = 19] |
0.9 (0.3) |
|
χ2 (p-value)2 |
1.7 (0.1) |
1.3 (0.2) |
1.7 (0.1) |
|
|
By residence |
||||
|
Rural |
84.0 (76.4–89.5) [N = 125] |
72.3 (63.9–79.4) [N = 130] |
54.9 (46.3–63.2) [N = 133] |
16.5 (< 0.001) |
|
S-Urban |
86.0 (72.1–93.6) [N = 43] |
70.7 (55.0–82.6) [N = 41] |
61.9 (46.4–75.3) [N = 42] |
3.5 (0.03) |
|
Urban |
86.4 (64.9–95.6) [N = 22] |
100 [N = 17] |
88.2 (62.9–97.1) [N = 17] |
1.2 (0.2) |
|
χ2 (p-value)2 |
0.07 (0.9) |
3.3 (0.03) |
3.5 (0.03) |
|
|
|
||||
|
χ2 (p-value)1 for difference between survey years χ2 (p-value)2 for difference within survey years |
||||
|
Marchant et al. Malaria Journal 2008 7:260 doi:10.1186/1475-2875-7-260 |
||||
